While the pharmacological management of chronic obstructive pulmonary disease (COPD)
has evolved from the drugs used to treat asthma, the treatment models are different and the …

Rationale: There is uncertainty on the optimal first-line therapy for symptomatic chronic
obstructive pulmonary disease (COPD). Long-acting β2-receptor agonists (LABAs) and long …

Background Despite the availability of national and international guidelines, evidence
suggests that chronic obstructive pulmonary disease (COPD) treatment is not always …

Background Real-world prescription pathways leading to triple therapy (TT)(inhaled
corticosteroid [ICS] plus long-acting β2-agonist bronchodilator [LABA] plus long-acting …

Study objectives The aim of this analysis was to understand the implications of the GOLD
2011 multidimensional system for the assessment and management of COPD, using data …

ABSTRACT OBJECTIVE We tested the hypothesis that use of and adherence to
maintenance medication is low among in-dividuals in the general population who have …

Adherence to Global Initiative for Chronic Obstructive Lung... : Current Opinion in Pulmonary
Medicine Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the …

Chronic obstructive pulmonary disease (COPD) is associated with major healthcare and
socioeconomic burdens. International consortia recommend a personalized approach to …

Background Regular use of inhaled corticosteroids (ICS) in patients with obstructive lung
diseases has been associated with a higher risk of pneumonia, particularly in COPD. The …

Background: Blood eosinophils may predict response to inhaled corticosteroids (ICS) in
chronic obstructive pulmonary disease (COPD) where ICS is recommended in patients at …